Theralase’s Rutherrin® Shows Promise in Preclinical Cancer Treatment

Theralase Technologies ( (TSE:TLT) ) has issued an announcement.

Theralase Technologies announced promising preclinical results for their X-Ray-activated drug, Rutherrin®, which has shown significant effectiveness in treating various cancers. The drug, when activated by radiation therapy, demonstrated enhanced tumor destruction, overcoming treatment resistance, and stimulating systemic immunity. These findings position Rutherrin® as a potential breakthrough in cancer treatment, with plans for further toxicology studies and clinical development targeting several aggressive cancers.

The most recent analyst rating on (TSE:TLT) stock is a Buy with a C$0.70 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.

Spark’s Take on TSE:TLT Stock

According to Spark, TipRanks’ AI Analyst, TSE:TLT is a Neutral.

Theralase Technologies’ overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. Technical analysis provides a neutral outlook, while valuation metrics highlight ongoing financial struggles. The absence of earnings call and corporate events data limits further insights.

To see Spark’s full report on TSE:TLT stock, click here.

More about Theralase Technologies

Theralase Technologies Inc. is a clinical stage pharmaceutical company focused on the research and development of light, radiation, sound, and drug-activated small molecule compounds. Their primary objective is to develop treatments for various cancers, bacteria, and viruses, prioritizing efficacy and safety with minimal impact on healthy tissue.

Average Trading Volume: 98,961

Technical Sentiment Signal: Hold

Current Market Cap: C$53.98M

Learn more about TLT stock on TipRanks’ Stock Analysis page.